Bli medlem
Bli medlem

Du är här

2016-10-14

FIT Biotech Oy: Correction to company release: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants

FIT Biotech Oy

Company release October 14, 2016 at 21.30 pm EET

Correction to company release: FIT Biotech Oy's Board of Directors has decided
on the issue of Convertible Notes and Warrants

FIT Biotech Oy's company release published on October 14, 2016 at 17.45 EET
contained an error related to the euro amount of the Convertible Notes with
Warrants Funding Programme between the Company and Sitra. The correct euro
amount is EUR 500,000.

FIT BIOTECH OY

Board of Directors

For further information:
Chairman of the Board of Directors Juha Vapaavuori
E-mail: juha.vapaavuori@fitbiotech.com
Tel: +358 50 372 0824

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company
develops and licenses its patented GTU® (Gene Transport Unit) vector
technology for new-generation medical treatments. GTU® is a gene transport
technology that meets an important medical challenge in the usability of gene
therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes.
Application areas include cancer (gene therapy) and infectious diseases such
as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace
maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
Nasdaq Helsinki
Principal media

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FIT Biotech Oy via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.